Cox proportional hazards model analysis of different CAR groups and incidence of endpoint events in the total population
| CAR groups | Events/total population | Incidence density/103 person-years | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) |
| CVD | ||||||
| Q1 | 773/15 614 | 4.79 | Ref | 1Ref | Ref | Ref |
| Q2 | 931/15 419 | 5.82 | 1.08 (0.98 to 1.19) | 1.01 (0.91 to 1.11) | 1.00 (0.91 to 1.10) | 1.00 (0.91 to 1.10) |
| Q3 | 1043/15 519 | 6.51 | 1.26 (1.15 to 1.38) | 1.07 (0.98 to 1.18) | 1.07 (0.98 to 1.18) | 1.07 (0.97 to 1.18) |
| Q4 | 1278/15 515 | 8.12 | 1.56 (1.42 to 1.71) | 1.27 (1.16 to 1.39) | 1.26 (1.15 to 1.38) | 1.24 (1.12 to 1.38) |
| Increase 1 SD | 1.08 (1.06 to 1.11) | 1.06 (1.03 to 1.08) | 1.06 (1.03 to 1.08) | 1.04 (1.00 to 1.07) | ||
| Acute myocardial infarction | ||||||
| Q1 | 143/15 614 | 0.89 | Ref | Ref | Ref | Ref |
| Q2 | 153/15 419 | 0.96 | 0.96 (0.76 to 1.21) | 0.87 (0.69 to 1.10) | 0.87 (0.69 to 1.09) | 0.87 (0.69 to 1.09) |
| Q3 | 215/15 519 | 1.34 | 1.40 (1.14 to 1.73) | 1.17 (0.95 to 1.45) | 1.17 (0.94 to 1.45) | 1.17 (0.94 to 1.45) |
| Q4 | 305/15 515 | 1.94 | 1.98 (1.63 to 2.42) | 1.61 (1.32 to 1.98) | 1.61 (1.31 to 1.97) | 1.63 (1.29 to 2.05) |
| Increase 1 SD | 1.12 (1.08 to 1.17) | 1.11 (1.06 to 1.16) | 1.11 (1.06 to 1.16) | 1.07 (1.01 to 1.14) | ||
| Stroke | ||||||
| Q1 | 630/15 614 | 3.90 | Ref | Ref | Ref | Ref |
| Q2 | 778/15 419 | 4.86 | 1.11 (1.00 to 1,23) | 1.04 (0.93 to 1.15) | 1.03 (0.93 to 1.14) | 1.03 (0.93 to 1.14) |
| Q3 | 830/15 519 | 5.18 | 1.23 (1.11 to 1.37) | 1.06 (0.95 to 1.17) | 1.05 (0.95 to 1.17) | 1.05 (0.95 to 1.17) |
| Q4 | 974/15 515 | 6.19 | 1.45 (1.31 to 1.60) | 1.19 (1.07 to 1.32) | 1.18 (1.07 to 1.31) | 1.15 (1.02 to 1.30) |
| Increase 1 SD | 1.07 (1.04 to 1.10) | 1.04 (1.01 to 1.07) | 1.04 (1.01 to 1.07) | 1.02 (0.98 to 1.06) | ||
| Haemorrhagic stroke | ||||||
| Q1 | 84/15 614 | 0.52 | Ref | Ref | Ref | Ref |
| Q2 | 79/15 419 | 0.49 | 0.85 (0.63 to 1.16) | 0.82 (0.61 to 1.09) | 0.81 (0.61 to 1.07) | 0.81 (0.61 to 1.07) |
| Q3 | 84/15 519 | 0.52 | 0.94 (0.69 to 1.27) | 0.88 (0.67 to 1.17) | 0.88 (0.67 to 1.16) | 0.88 (0.67 to 1.16) |
| Q4 | 97/15 515 | 0.62 | 1.09 (0.81 to 1.46) | 0.96 (0.73 to 1.27) | 0.95 (0.72 to 1.25) | 0.98 (0.71 to 1.36) |
| Increase 1 SD | 1.06 (0.98 to 1.15) | 1.06 (0.98 to 1.14) | 1.06 (0.98 to 1.14) | 1.05 (0.94 to 1.18) | ||
| Ischaemic stroke | ||||||
| Q1 | 565/15 614 | 3.50 | Ref | Ref | Ref | Ref |
| Q2 | 716/15 419 | 4.47 | 1.14 (1.02 to 1.27) | 1.07 (0.95 to 1.20) | 1.06 (0.95 to 1.19) | 1.05 (0.95 to 1.19) |
| Q3 | 766/15 519 | 4.78 | 1.27 (1.14 to 1.41) | 1.08 (0.97 to 1.21) | 1.08 (0.97 to 1.21) | 1.08 (0.97 to 1.21) |
| Q4 | 895/15 515 | 5.68 | 1.49 (1.34 to 1.65) | 1.22 (1.09 to 1.36) | 1.22 (1.09 to 1.36) | 1.19 (1.05 to 1.35) |
| Increase 1 SD | 1.07 (1.04 to 1.10) | 1.04 (1.01 to 1.07) | 1.04 (1.01 to 1.07) | 1.02 (0.98 to 1.06) | ||
Model 1 adjusted for age (continuous) and gender (male or female); Model 2 further adjusted for smoking (yes or no), alcohol intake ≥36 mL/day (yes or no), physical exercise (yes or no), higher education (yes or no), body mass index (<28 kg/m2, ≥28 kg/m2), hypertension (yes or no), diabetes (yes or no), low-density lipoprotein cholesterol (continuous), high-density lipoprotein cholesterol (continuous), estimated glomerular filtration rate (<60 mL/min, ≥60 mL/min), alanine aminotransferase (continuous) on the basis of model 1; model 3 further adjusted for hypertensive drugs (yes or no), hypoglycaemic drugs (yes or no), and lipid-lowering drugs (yes or no) on the basis of model 2; model 4 further adjusted for hs-CRP (continuous) and albumin (continuous) in 2010 based on model 3.
Bold font indicated statistical significance with p<0.05.
CAR, high-sensitivity C reactive protein to albumin ratio; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; hs-CRP, high-sensitivity C reactive protein; Increase 1 SD, increase high-sensitivity C reactive protein to albumin ratio by 1-unit standard deviation.